Lineage Cell Therapeutics
LCTX
115 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2018 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 11 closing their positions.
151% more call options, than puts
Call options by funds: $349K | Put options by funds: $139K
21% more capital invested
Capital invested by funds: $125M → $152M (+$26.7M)
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.55% less ownership
Funds ownership: 52.41% → 50.87% (-1.5%)
2% less funds holding
Funds holding: 117 → 115 (-2)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$1.75M |
| 2 |
IA
IndexIQ Advisors
New York
|
+$1.1M |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
+$652K |
| 4 |
LCM
Laurion Capital Management
New York
|
+$470K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$233K |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$3.35M |
| 2 |
Renaissance Technologies
New York
|
-$1.13M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$904K |
| 4 |
Two Sigma Investments
New York
|
-$471K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$359K |
LCTX Hedge Fund Activity: Q1 2018 in Review
115 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2018, worth a combined $152M — up 21% from $125M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of LCTX and 9 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 36 added.
The largest buyer was State Street, adding an estimated $1.75M. The largest seller was Artal Group, exiting entirely with an estimated $3.35M sold.
- 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2018, down from 117 in Q4 2017.
- Funds reported $152M of Lineage Cell Therapeutics stock for Q1 2018, up 21% quarter-over-quarter.
- 9 funds opened new Lineage Cell Therapeutics positions in Q1 2018 and 11 closed out, a net change of -2 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2018 was State Street, an estimated $1.75M added.
- The largest Lineage Cell Therapeutics seller in Q1 2018 was Artal Group, an estimated $3.35M sold.
Based on aggregated 13F filings for Q1 2018.